<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Gri Bio Inc. — News on 6ix</title>
<link>https://6ix.com/company/gri-bio-inc</link>
<description>Latest news and press releases for Gri Bio Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/gri-bio-inc" rel="self" type="application/rss+xml" />
<item>
<title>GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions</guid>
<pubDate>Wed, 08 Apr 2026 12:30:00 GMT</pubDate>
<description>Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a N</description>
</item>
<item>
<title>GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-ceo-marc-hertz-141500097</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-ceo-marc-hertz-141500097</guid>
<pubDate>Tue, 17 Feb 2026 14:15:00 GMT</pubDate>
<description>Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment. As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI</description>
</item>
<item>
<title>GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-participate-corporate-connect-141500204</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-participate-corporate-connect-141500204</guid>
<pubDate>Thu, 05 Feb 2026 14:15:00 GMT</pubDate>
<description>– Live video webcast on Wednesday, February 11th at 1:00 PM EST LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation</description>
</item>
<item>
<title>GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-reiterates-full-2025-134500265</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-reiterates-full-2025-134500265</guid>
<pubDate>Wed, 04 Feb 2026 13:45:00 GMT</pubDate>
<description>Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIR</description>
</item>
<item>
<title>GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-delivers-compelling-phase-134500269</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-delivers-compelling-phase-134500269</guid>
<pubDate>Wed, 28 Jan 2026 13:45:00 GMT</pubDate>
<description>Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fib</description>
</item>
<item>
<title>GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-secures-u-composition-133000259</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-secures-u-composition-133000259</guid>
<pubDate>Mon, 26 Jan 2026 13:30:00 GMT</pubDate>
<description>Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,528,775,</description>
</item>
<item>
<title>GRI Bio Announces Reverse Stock Split</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-reverse-stock-210100201</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-reverse-stock-210100201</guid>
<pubDate>Wed, 21 Jan 2026 21:01:00 GMT</pubDate>
<description>GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the “Reverse Split”) of the Company’s commo</description>
</item>
<item>
<title>GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-additional-positive-130000737</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-additional-positive-130000737</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced positive flow cytometry data from the Phase 2a GRI-0621-IPF-02 clinical</description>
</item>
<item>
<title>GRI Bio Announces Closing of $8.0 Million Public Offering</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-closing-8-210500307</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-closing-8-210500307</guid>
<pubDate>Fri, 12 Dec 2025 21:05:00 GMT</pubDate>
<description>LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 s</description>
</item>
<item>
<title>GRI Bio Announces Pricing of $8,000,000 Million Public Offering</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-pricing-8-141500435</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-pricing-8-141500435</guid>
<pubDate>Thu, 11 Dec 2025 14:15:00 GMT</pubDate>
<description>LA JOLLA, CA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a best efforts public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof) and Series F warrants to purchase up to 10,666,667 shares o</description>
</item>
<item>
<title>GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-positive-topline-210500497</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-announces-positive-topline-210500497</guid>
<pubDate>Wed, 10 Dec 2025 21:05:00 GMT</pubDate>
<description>Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing approved treatments Study met its secondary endpoints and demonstrated improvement in biomarkers of collagen turnover, suggesting a resolution of fibrosis and repair of the alveolar basement membrane GRI-0621 demonstrated increases in forced vital capacity (FVC) at 6 and 12 weeks of tre</description>
</item>
<item>
<title>GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-reports-6-week-124500898</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-reports-6-week-124500898</guid>
<pubDate>Thu, 11 Sep 2025 12:45:00 GMT</pubDate>
<description>No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovati</description>
</item>
<item>
<title>GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-present-h-c-130000245</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-present-h-c-130000245</guid>
<pubDate>Wed, 03 Sep 2025 13:00:00 GMT</pubDate>
<description>Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at 3:00 PM ET on Tuesday, September 9, 2025 at the H.</description>
</item>
<item>
<title>GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-present-webull-financial-131500505</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-present-webull-financial-131500505</guid>
<pubDate>Thu, 14 Aug 2025 13:15:00 GMT</pubDate>
<description>Live video webcast on Wednesday, August 20th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation</description>
</item>
<item>
<title>GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-ceo-marc-hertz-175000808</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-ceo-marc-hertz-175000808</guid>
<pubDate>Thu, 31 Jul 2025 17:50:00 GMT</pubDate>
<description>Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discus</description>
</item>
<item>
<title>GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-reports-6-week-130000237</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-reports-6-week-130000237</guid>
<pubDate>Thu, 31 Jul 2025 13:00:00 GMT</pubDate>
<description>Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient com</description>
</item>
<item>
<title>GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-participates-virtual-investor-124500361</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-participates-virtual-investor-124500361</guid>
<pubDate>Tue, 22 Jul 2025 12:45:00 GMT</pubDate>
<description>– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI BIO, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Confere</description>
</item>
<item>
<title>GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-completes-enrollment-phase-124500000</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-completes-enrollment-phase-124500000</guid>
<pubDate>Tue, 01 Jul 2025 12:45:00 GMT</pubDate>
<description>Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety results demonstrated GRI-0621 to be safe and well-tolerated in the first 12 and 24 patients evaluated, respectively Results on track for 6-week interim biomarker analysis (n=24) in July 2025 and topline data in Q3 2025 LA JOLLA, CA, July 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GR</description>
</item>
<item>
<title>GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-gri-0621-demonstrates-120000162</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-gri-0621-demonstrates-120000162</guid>
<pubDate>Thu, 26 Jun 2025 12:00:00 GMT</pubDate>
<description>The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited p</description>
</item>
<item>
<title>GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results</title>
<link>https://6ix.com/company/gri-bio-inc/news/gri-bio-presents-positive-pre-120000042</link>
<guid isPermaLink="true">https://6ix.com/company/gri-bio-inc/news/gri-bio-presents-positive-pre-120000042</guid>
<pubDate>Thu, 22 May 2025 12:00:00 GMT</pubDate>
<description>Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company</description>
</item>
</channel>
</rss>